Mark Ratner

30 Years of Experience


A frequent contributor to MedTech Strategist and Market Pathways, Mark Ratner specializes in personalized medicine, molecular diagnostics, oncology, and neurology. He is an editorial adviser and frequent contributor to Nature Biotechnology, where he began his career in biotech in 1988 as a news editor. For most of the 1990s, Mark worked for and consulted to biotech companies in the Boston area.

Articles from Mark Ratner:

Investors & Dealmaking

Boston Scientific Aims High in Oncology

Although 2018 sales of Boston Scientific’s current interventional oncology products were barely worth a mention in recent financial disclosures, it hopes, with the acquisition of BTG, to become a significant player in oncology to help sustain the growth investors are now expecting.

Read Article